RG 7990

Drug Profile

RG 7990

Alternative Names: BITS 7201A; RG7990; RO 7040547

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NovImmune SA
  • Developer Genentech; NovImmune SA
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma

Most Recent Events

  • 14 Jun 2017 Genentech completes a phase I trial for Allergic asthma in USA (SC and IV) (NCT02748642)
  • 19 Apr 2016 Genentech plans a phase I trial for Allergic asthma in USA (SC and IV) (NCT02748642)
  • 07 Apr 2016 Phase-I clinical trials in Allergic asthma in USA (IV) (Genentech pipeline, September 2016) (NCT02748642)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top